New drug with chemotherapy and radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the experimental drug becotatug vedotin to standard chemotherapy and radiation therapy can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma. It may help shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell carcinoma of the esophagus (a type of esophageal cancer).
- You have not received any previous treatment for this cancer.
- Your cancer has not spread beyond the esophagus or to just the lymph nodes above the collarbone.
- You are able to perform daily activities with some effort (ECOG status 0 or 1).
- You have adequate liver, kidney, and blood function.
- You are not pregnant or breastfeeding and are willing to use effective contraception during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a new combination of two chemotherapy drugs (liposomal irinotecan and cisplatin) given together with radiation therapy for locally advanced esophageal cancer. It aims to see if this treatment is safe and effective, potentially offering a new option for patients who cannot have surgery.
This trial tests a combination of two drugs (cadonilimab and anlotinib) followed by radiation therapy for esophageal cancer that has returned or spread. The goal is to see if this approach helps shrink tumors and control the disease.
This study tests a new drug called becotatug vedotin, added to standard chemotherapy, for advanced bile duct cancer that has a specific protein called EGFR. The goal is to see if this combination helps shrink tumors or slow the cancer better than standard treatment alone.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.